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Abstract 
Background: Sub-Saharan Africa remains the region with the highest child mortality rate in the world. 
Most commonly, pneumonia, diarrhea, and malaria rank among the leading causes of preventable deaths 
in this population. The World Health Organization (WHO) recommends mass drug administration (MDA) 
of azithromycin, a broadspectrum macrolide antibiotic, for the treatment of trachoma. Some studies 
suggest that MDA of azithromycin for this purpose has the added benefit of protection against other 
illnesses including malaria, diarrheal episodes, and respiratory infections. The aim of this review is to 
investigate the effect of MDA of azithromycin on mortality rates in African children. 
Methods: An exhaustive search of available medical literature was performed using MEDLINE-Ovid, 
CINHAL, and Web of Science databases. Relevant search terms included ‘azithromycin,’ ‘child*,’ ‘mortality,’ 
and ‘mass.’ The quality of relevant articles was assessed using the GRADE Working Group guidelines. 
Results: A total of 3 studies, 2 randomized control trials (RCT) and 1 observational analysis, were included 
in this review. One RCT conducted in Malawi, Niger, and Tanzania showed that all-cause mortality rates 
declined in children ages 1-59 months after azithromycin administration, with the greatest benefit seen in 
children ages 1-5 months. Another RCT revealed similar findings, with decreased all-cause mortality rates 
in children ages 1-9 years in Ethiopia after MDA of azithromycin. A retrospective observational analysis 
also suggested reduced all-cause and infectious mortality rates in children ages 1-5 years in Ethiopia 
after azithromycin treatment. 
Conclusion: MDA of azithromycin in African communities decreases all-cause mortality rates in children 
ages 1-5 years. Additional studies are needed to assess short and long-term adverse outcomes of MDA 
and the effect of MDA on antibiotic resistance. 
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Abstract 
Background: Sub-Saharan Africa remains the region with the highest child mortality 
rate in the world. Most commonly, pneumonia, diarrhea, and malaria rank among the 
leading causes of preventable deaths in this population. The World Health Organization 
(WHO) recommends mass drug administration (MDA) of azithromycin, a broad-
spectrum macrolide antibiotic, for the treatment of trachoma. Some studies suggest that 
MDA of azithromycin for this purpose has the added benefit of protection against other 
illnesses including malaria, diarrheal episodes, and respiratory infections. The aim of 
this review is to investigate the effect of MDA of azithromycin on mortality rates in 
African children. 
Methods: An exhaustive search of available medical literature was performed using 
MEDLINE-Ovid, CINHAL, and Web of Science databases. Relevant search terms 
included ‘azithromycin,’ ‘child*,’ ‘mortality,’ and ‘mass.’ The quality of relevant articles 
was assessed using the GRADE Working Group guidelines. 
Results: A total of 3 studies, 2 randomized control trials (RCT) and 1 observational 
analysis, were included in this review. One RCT conducted in Malawi, Niger, and 
Tanzania showed that all-cause mortality rates declined in children ages 1-59 months 
after azithromycin administration, with the greatest benefit seen in children ages 1-5 
months. Another RCT revealed similar findings, with decreased all-cause mortality rates 
in children ages 1-9 years in Ethiopia after MDA of azithromycin. A retrospective 
observational analysis also suggested reduced all-cause and infectious mortality rates in 
children ages 1-5 years in Ethiopia after azithromycin treatment. 
Conclusion: MDA of azithromycin in African communities decreases all-cause 
mortality rates in children ages 1-5 years. Additional studies are needed to assess short 
and long-term adverse outcomes of MDA and the effect of MDA on antibiotic resistance. 
Keywords: Africa, azithromycin, child*, MDA, mortality 
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Mass Distribution of Azithromycin Reduces Mortality in 
African Children 
BACKGROUND 
 Pneumonia, diarrhea, and malaria rank among the most common preventable 
causes of death in children worldwide.1 Combined, these infectious diseases account for 
over 30 percent of deaths in children less than 5 years old, with most deaths occurring 
in sub-Saharan Africa and South Asia. In 2013, the World Health Organization (WHO) 
even created a global action plan outlining measures to end child deaths due to 
pneumonia and diarrhea by 2025. Such measures include improving sanitation and 
hygiene, ensuring vaccination against respiratory illnesses, and proper treatment of 
diarrhea via oral rehydration salts and zinc supplements.2 In addition, insecticide-
treated bed nets have been introduced to countries endemic to malaria, which accounts 
for 7 percent of under-five deaths each year.2,3  
 Despite these efforts, sub-Saharan Africa remains the region with the highest 
child mortality rate in the world. In fact, 1 in every 13 children will die before their fifth 
birthday. With such high child mortality rates, the need for further research regarding 
prevention and treatment of preventable diseases continues to be a top public health 
priority in the realm of global health.1 
 The WHO already recommends mass drug administration (MDA) of 
azithromycin, a broad-spectrum macrolide antibiotic, for the treatment of trachoma.4,5 
Trachoma is an infection of the eye caused by Chlamydia trachomatis that causes 
permanent blindness.4 Although found in rural and poor regions worldwide, trachoma is 
most prevalent in Africa, with more than 26 affected countries on the continent.6 Some 
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studies suggest that MDA of azithromycin for the purpose of trachoma control has the 
added benefit of protection against other illnesses including malaria and diarrheal 
episodes.7–9 Another study showed that azithromycin may also reduce infection by S. 
pneumoniae in Gambian children, thereby decreasing mortality rates due to 
pneumonia.5 
 The mechanism by which azithromycin prevents against these diseases is still 
unknown,10 however, its use as prophylactic agent against high-mortality diseases 
warrants investigation. The purpose of this review is to determine the effect of mass 
distribution of azithromycin on child mortality rates in Africa and to contrast the risks 
and benefits of this protocol. 
METHODS 
 An exhaustive search of available medical literature was performed using 
MEDLINE-Ovid, CINHAL, and Web of Science databases. Relevant search terms 
included azithromycin, child*, mortality, and mass. Included studies were those 
involving children in Africa, evaluating MDA of azithromycin compared to placebo or no 
treatment, and assessing child mortality rates. Other inclusion criteria included English 
language articles, articles published within the past 10 years (2008-2018), and age of 
children (e.g. 0-12 yo). References listed in the included articles were searched for 
additional articles. Relevant articles were assessed using the Grading of 
Recommendations, Assessment, Development, and Evaluation (GRADE) guidelines.11 
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RESULTS 
 The initial search resulted in 39 articles. Application of inclusion criteria and 
removal of duplicate articles yielded 3 relevant studies: two cluster-randomized clinical 
trials (RCT)12,13 and one cohort observational analysis.14 
Keenan et al (2018) 
 This cluster RCT12 assessed all-cause mortality rates between children who 
received MDA of azithromycin compared to those who received placebo in Malawi, 
Niger, and Tanzania. Communities in each country were allocated to either the 
azithromycin treatment or placebo group. Within these communities, children ages 1-59 
months weighing at least 3800 g who had not previously received azithromycin for 
trachoma control purposes, or otherwise, were eligible to participate. Children with 
known macrolide allergies were excluded. Children were provided either a weight-based 
dose of azithromycin or placebo twice each year, during the length of this 2-year study.  
Randomization was concealed and participants, observers, investigators, and data 
collectors were blinded to group allocation.12 
 The primary outcome of this study was all-cause mortality rate, which was 
assessed during a twice-yearly census conducted by the investigators. The status of each 
participant was recorded as alive, dead, or unknown at each census. Verbal autopsies 
were attained in order to assess cause of death.12 
 Between the 3 countries, 1533 communities were included, totaling 190,238 
children, or 323,302 person-years over the course of 2 years. The study showed that 
mortality amongst all 3 countries was 13.5% lower in children treated with azithromycin 
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compared to the placebo group (95% CI, 6.7 to 19.8). The overall annual mortality rate 
was 16.5 deaths per 1000 person-years in children receiving placebo and 14.6 deaths per 
1000 person-years in azithromycin treated children. These findings were most 
significant in Niger. In this country, the azithromycin treated group exhibited a 
mortality rate 18.1% lower compared to children who received placebo (P<0.001). This 
finding was notable enough to prompt the investigators to offer azithromycin to all 
participants in Niger at the end of the  study.12 
 The researchers also studied mortality rates by age group. Children ages 1-5 
months experienced the highest mortality rates among all 3 countries. This age group 
also exhibited the greatest benefit from treatment with azithromycin. Mortality rates 
were 24.9% lower in the azithromycin treated group compared to children who did not 
receive the antibiotic (95% CI, 10.6 to 37.0; P=0.001).12  
Porco et al (2009) 
 This cluster RCT13 evaluated mortality rates in children ages 1-9 years who 
received annual, biannual, or quarterly administration of azithromycin for trachoma 
control compared to children who received no treatment. The study took place over the 
course of 1 year in Ethiopia. Whole communities, not just children, were randomized to 
1 of the 3 treatment groups or the control group. Participants who were pregnant or had 
known macrolide allergies were excluded.13 
 The primary outcome was mortality risk. This was assessed by personnel who 
conducted a census at the onset of the trial and another after 1 year’s time to address 
absent participants. Causes of death were evaluated by verbal autopsy.13 
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 A total of 48 communities, comprised of 18,415 children ages 1-9 years old, were 
included in the analysis. The authors concluded that, in 1-9 year-olds, the overall 
mortality rate in the control group was 8.3 per 1000 person-years (95% CI, 5.3-13.1) 
compared to 4.1 per 1000 person-years (95% CI, 3.0-5.7) in the azithromycin treated 
group. Using negative binomial regression, this equates to a 50% lower mortality rate in 
children treated with MDA.  Analysis of children ages 1-5 years who received treatment 
revealed a similar reduction in mortality. The mortality rate in the untreated group was 
12.1 per 1000 person-years (95% CI, 7.4-19.6) compared to the 5.7 per 1000 person-
years (95% CI, 4.1-8.0) in azithromycin treated group. While the authors did not 
explicitly address the effect size of each treatment limb, the lowest mortality rate was 
observed in children receiving only the annual dose of azithromycin compared to 
biannual or quarterly MDA (3.2, 4.9, and 4.7 per 1000 person-years, respectively).13 
Keenan et al (2011) 
 This observational analysis14 is based on a subset of 24 Ethiopian communities in 
Porco et al’s (2009)13 RCT, which examined the use of azithromycin in the setting of 
trachoma control. In that study, individuals over the age of 1 year were eligible to receive 
a single dose of azithromycin. Approximately 89% of the entire cohort, and 83% of 
children ages 1-5 received MDA of azithromycin. Individuals who did not receive 
treatment included those were ill during the time of administration, those who received 
topical tetracycline (due to pregnancy or macrolide allergy), individuals who refused 
treatment, or those who were alive but did not receive treatment for some other reason. 
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 Keenan et al (2011) analyzed a total of 35,052 participants, including 5,507 
children ages 1-5 years old. The primary outcomes were all-cause and infectious 
mortality rates (defined as deaths per 1000 person-years). These outcomes were 
assessed by census workers 26 months after the treatment dose. Verbal autopsies were 
conducted to assess causes of death, which were classified as respiratory illness, 
diarrhea, malaria, old age, accidental, or unknown.14 
 The authors examined all-cause and infectious mortality rates by age group. All-
cause mortality rates were lower in children ages 1-5 who received azithromycin (2.79 
deaths per 1000 person-years, CI, 1.90-4.09) compared to children in the same age 
group who did not receive treatment (8.18 deaths per 1000 person-years, CI, 
4.34-15.34). This finding was statistically significant (P=0.006). Similarly, mortality due 
to infection was significantly lower in children ages 1-5 who received MDA of 
azithromycin (0.89 deaths per 1000 person years , CI, 0.36-2.15) as opposed to those 
who did not (4.86 deaths per 1000 person years, CI 2.09-11.27). In all other age groups 
(6-10 years, 10-20 years, and >20 years), participants who received azithromycin 
actually had higher all-cause mortality rates (OR 1.42, 1.40, and 1.26, respectively). 
Mortality rates due to infectious causes, however, were lower in all other age groups, 
although these findings were not significant.14 
DISCUSSION 
 Overall, the 3 studies12–14 evaluated in this review suggest that MDA of 
azithromycin reduces mortality in children, although the effect size differed greatly 
(Table 2). Keenan et al (2018)12 found that all-cause mortality rates decreased 13.5% in 
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children aged 1-5 years treated with azithromycin, although the greatest mortality 
reduction was observed in children ages 1-5 months. In comparison, Porco et al (2009)13 
and Keenan et al (2011)14 noted a 47% and 65% decrease, respectively, in all-cause 
mortality rates in children ages 1-5. Keenan et al (2011)14  also noted that mortality due 
to infectious causes was 80% less likely in azithromycin-treated children compared to 
children receiving placebo. 
 This difference in effect may, in part, be due to the fact that these studies were 
conducted in different countries. Keenan et al (2018)12 analyzed the mortality rates of 
children in Malawi, Niger, and Tanzania, while Porco et al (2009)13 and Keenan et al 
(2011)14 based their studies in Ethiopia. Inherent differences between populations and 
health risks specific to each country could have impacted mortality rates. As such, care 
should be taken when extrapolating the results of one study to all African countries, or 
even other regions of the world. 
 One of the major limitations of all 3 studies12-14 is the lack of individual health 
indices recorded for participants. Both RCTs12,13 were cluster-randomized trials, which 
can inherently introduce bias through an imbalance of variables at baseline.15 Both 
Keenan et al (2018)12 and Porco et al (2009)13 adjusted for this using clustered logistic 
regression and negative binomial regression in their statistical analyses. Porco et al 
(2009)13 also addressed some community factors that could influence individual 
mortality rates. For example, altitude of each community was analyzed, as a particular 
fly known to transmit infections favors higher altitudes. Despite these adjustments, a 
comparison of health indices would be useful in evaluating the similarity between 
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treatment and control groups to account for any baseline imbalances, as well as to 
compare populations across studies. 
 All 3 studies12-14 determined causes of death by verbal autopsies, which were 
conducted by census personnel. The accuracy of verbal autopsies is questionable, as 
conclusions were drawn from a constellation of symptoms prior to death and may not 
have correctly identified the actual cause of death in some cases. Regardless, all 3 
articles cited12-14 pneumonia, diarrhea, and respiratory illness as the 3 primary 
infectious causes of child deaths, albeit in differing proportions. These findings are 
consistent with the leading causes of childhood mortality identified worldwide.1 
 Although Keenan et al (2011)14 published the largest reduction in childhood 
mortality after azithromycin administration, this observational analysis was down-
graded to very low quality evidence due to poor methodology. Azithromycin treatment 
was not randomly allocated. Rather, participants were only allotted to the no-treatment 
group if they refused treatment, were pregnant, allergic to macrolides, or were ill or not 
present during the time of administration. The authors acknowledged that lack of 
randomization is a source of bias in this study. In particular, refusal to receive antibiotic 
treatment may be correlated with other factors that increase mortality, including 
poverty and lack of healthcare. Therefore, the findings of this study should not be 
weighted as heavily as the findings of other 2 RCTs in this review. 
 The study conducted by Porco et al (2009)13 also has its limitations, including a 
lack of blinding throughout the study. As a result, this RCT was downgraded to 
moderate quality evidence. Census personnel were unaware of treatment allocations and 
community randomization was concealed initially. However, field teams were ultimately 
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unmasked to treatment protocols. Additionally, participants were not blinded. Dose 
regimens were apparent and placebo doses were not provided for participants receiving 
annual or biannual administration to coincide with quarterly administration. Placebo 
antibiotic was not provided to the control group either. This study design makes it 
difficult to assess a placebo effect on mortality rates. Lastly, the short duration of the 
study makes it difficult to extrapolate these findings beyond one year and prompts 
further investigation to address the stability of these findings long-term. 
 Keenan et al (2018)12 reported that cause of death varied between countries 
included in their trial. Malaria was the leading cause of death in Niger, while pneumonia 
was the main cause of death in Tanzania. This, combined with the fact that Niger had 
the most significant reduction in mortality with treatment, suggests that azithromycin 
may play a larger role in malaria prevention compared to prevention of other infectious 
diseases. Further investigation into the mechanism of azithromycin is needed to better 
understand which diseases are most susceptible to the antibiotic. In turn, this may help 
us target populations that would benefit most from MDA of azithromycin. 
 Furthermore, Keenan et al (2018)12 included children ages 1-59 months in their 
study. Although the greatest benefit of treatment was noted in children ages 1-5 months, 
administration of azithromycin for trachoma control is not currently recommended by 
the WHO, nor is the antibiotic approved by the FDA, for use in this age group.4 Some 
studies17 suggest that azithromycin increases the risk of hypertrophic pyloric stenosis in 
infants. Because this age group has the most to gain from MDA of azithromycin, 
additional studies are needed to address this risk and other potential consequences of 
azithromycin administered to infants. 
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 The studies assessed in this review did not address the side effects of MDA of 
azithromycin. Keenan et al (2018)12 advised participants to report adverse events that 
occurred during the course of the trial. Although 20 hospitalizations and serious 
conditions were reported, it could not be determined whether they were caused by 
azithromycin. Some studies16 suggest a link between azithromycin and deaths due to 
cardiac events in adults. Although this data may not be applicable to the population 
addressed in this review, future studies should consider adverse effects and long-term 
outcomes of MDA of azithromycin to assess the safety of this protocol. 
 Perhaps one of the most significant implications of MDA of azithromycin is its 
impact on antibiotic resistance, which remains largely unknown. One study18 observed 
that azithromycin-resistant strains of Streptococcus pneumoniae increased after 
treatment with azithromycin for trachoma control. Another study19 suggested that MDA 
of azithromycin in the setting of trachoma control did not contribute to azithromycin-
resistant strains of Chlamydia trachomatis two months after treatment. Keenan et al 
(2018)12 also noted that the reduction in mortality rates actually increased during the 
course of the trial, providing little evidence to support to emergence of azithromycin-
resistant strains. Studies with longer follow-up periods are needed to fully assess 
whether this increase in mortality reduction is reproducible and sustainable. 
 Separately, the results from Keenan et al (2011)14 suggest that the lowest 
mortality rate was observed in children receiving only the annual dose of azithromycin 
compared to biannual or quarterly MDA. Although this finding should be taken lightly 
due to the very low quality of this study, it suggests that minimizing the number of 
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azithromycin doses given is actually more effective in protecting against infectious 
diseases and may help reduce the risk of antibiotic resistance. 
CONCLUSION 
 MDA of azithromycin for trachoma control in African children appears to have 
additional benefits. Specifically, the studies examined in this systematic review showed 
that all-cause mortality rates decreased in children ages 1-5 years who received 
azithromycin treatment. Considering MDA of azithromycin is already recommended by 
the WHO for trachoma control in endemic regions in Africa, reduced mortality among 
children is an added benefit of this protocol. Although the results of this research is 
promising, further investigation is needed to address adverse outcomes and antibiotic 
resistance related to MDA of azithromycin.  
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Tables 
Table 1: Quality Assessment of Reviewed Articles
Study Design
Downgrade Criteria
Quality
Limitations Indirectness Inconsistency Imprecision Publication Bias
Keenan et 
al (2018)
RCT Not serious Not serious Not serious Not serious Unlikely High
Porco et al 
(2009)
RCT Seriousa Not serious Not serious Not serious Unikely Moderate
Keenan et 
al (2011)
Cohort Seriousb Not serious Not serious Not serious Unlikely Very low
aLack of blinding of field team and participants; no mention of blinding of investigators 
bFailure to identify all known prognostic factors in participants and rule out as confounding variables
Table 2: Mortality Rates* amongst Children Receiving Azithromycin vs. Placebo
Study Age Range Country Azithromycin Treated Placebo
Keenan et al (2018) 1-5 years old Malawi 9.1 9.6
Niger 22.5 27.5
Tanzania 5.4 5.5
Overall 14.6 16.5
Porco et al (2009) 1-5 years old Ethiopia 5.7 12.1
1-9 years old 4.1 8.3
Keenan et al (2011) 1-5 years old Ethiopia 2.79 8.18
*Mortality rates reported as deaths per 1,000 person-years
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